January 10, 2012Clinical Cancer ResearchOpen Access

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Abstract

Crizotinib resistance in ALK(+) NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Doebele et al. (2012) studied this question.

synapsesocial.com/papers/69dc3a568df84278519f5344 https://doi.org/10.1158/1078-0432.ccr-11-2906

View Full Paper

Ask AI

Bookmark

Abstract

Crizotinib resistance in ALK(+) NSCLC occurs through somatic kinase domain mutations, ALK gene fusion CNG, and emergence of separate oncogenic drivers.

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Abstract

Discussion

Cite This Study

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

Abstract

Discussion

Cite This Study

Also Consider

Also Consider